patients with type 2 diabetes
Conditions
Interventions
PET/MRI examination for patients taking metformin
Sponsors
Kobe university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with type 2 diabets (2) Patients taking moore than 1000 mg of metformin per day last month or more (3) Patients with no obvious lesions in the lower gastrointestinal tract (4) Age more than 20 years old (5) Patients who have given their voluntary written consent to participate in this clinical study
Exclusion criteria
Exclusion criteria: (1) Patients who participated in other clinical trials within 3 months prior to obtaining consent (2) Patients suffering from dementia or mental illness (3) Patients with possible bowel perforation or obstruction (4) Patients with metals in the body that are not amenable to PET/MRI testing (5) Pregnant or breast feeding patients (6) Other patients who are deemed inappropriate by the investigators of this clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| site of excretion pathway in the intestinal tract of fluorodeoxyglucose(FDG) | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical parameters of HbA1c, blood glucose level, biochemical test items, background factors of study subjects | — |
Countries
Japan
Contacts
Public ContactKazuhiko Sakaguchi
Kobe university Department of Diabetes and Endocrinology
Outcome results
None listed